<?xml version="1.0" encoding="UTF-8"?>
<p id="Par10">Abnormally high levels of IL-6 are an indicator of poor outcome in COVID-19 patients with pneumonia and ARDS [
 <xref ref-type="bibr" rid="CR23">23</xref>]. Tocilizumab (ActemraÂ®) is a recombinant humanized anti-human IL-6 receptor monoclonal antibody that can specifically bind the membrane-bound IL-6 receptor (mIL6R) and soluble IL-6 receptor (sIL6R), thereby inhibiting signal transduction [
 <xref ref-type="bibr" rid="CR24">24</xref>]. Tocilizumab is currently FDA-approved for the management of RA, giant cell arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis [
 <xref ref-type="bibr" rid="CR24">24</xref>]. It is also approved for the management of chimeric antigen receptor (CAR) T-cell-induced CRS [
 <xref ref-type="bibr" rid="CR24">24</xref>], making it a possible therapeutic option for CRS of severely ill COVID-19 patients who have extensive lung lesions and high IL-6 levels [
 <xref ref-type="bibr" rid="CR25">25</xref>].
</p>
